排序方式: 共有419条查询结果,搜索用时 46 毫秒
71.
Erwan Salaun Laura Sportouch Pierre-Antoine Barral Sandrine Hubert Cécile Lavoute Anne-Claire Casalta Julie Pradier Daniel Ouk Jean-Paul Casalta Marc Lambert Frédérique Gouriet Jean-Yves Gaubert Aurélie Dehaene Alexis Jacquier Laetitia Tessonnier Julie Haentjens Alexis Theron Alberto Riberi Gilbert Habib 《JACC: Cardiovascular Imaging》2018,11(1):143-146
72.
Andras P. Durko Ruben L. Osnabrugge A. Pieter Kappetein 《Trends in Cardiovascular Medicine》2018,28(3):174-183
Transcatheter aortic valve replacement (TAVR) revolutionized the treatment of severe symptomatic aortic stenosis (AS). TAVR is increasingly offered for lower-risk patients. The role and place of TAVR in the future treatment of AS is not clear yet. In this review, we discuss the long-term outlook for TAVR, its challenges and its relationship to conventional surgical aortic valve replacement. 相似文献
73.
Simone A. Huygens Jonathan R.G. Etnel Milad Hanif Jos A. Bekkers Ad J.J.C. Bogers Maureen P.M.H. Rutten-van Mölken Johanna J.M. Takkenberg 《The Journal of thoracic and cardiovascular surgery》2019,157(6):2189-2197.e14
ObjectiveTo support decision-making in aortic valve replacement (AVR) in elderly patients, we provide a comprehensive overview of outcome after AVR with bioprostheses.MethodsA systematic review was conducted of studies reporting clinical outcome after AVR with bioprostheses in elderly patients (mean age ≥70 years; minimum age ≥65 years) published between January 1, 2000, to September 1, 2016. Reported event rates and time-to-event data were pooled and entered into a microsimulation model to calculate life expectancy and lifetime event risks.ResultsForty-two studies reporting on 34 patient cohorts were included, encompassing a total of 12,842 patients with 55,437 patient-years of follow-up (pooled mean follow-up 5.0 ± 3.3 years). Pooled mean age was 76.5 ± 5.5 years. Pooled early mortality risk was 5.42% (95% confidence interval [CI], 4.49-6.55), thromboembolism rate was 1.83%/year (95% CI, 1.28-3.61), and bleeding rate was 0.75%/year (95% CI, 0.50-1.11). Structural valve deterioration (SVD) was based on pooled time to SVD data (Gompertz; shape: 0.124, rate: 0.003). For a 75-year-old patient, this translated to an estimated life expectancy of 9.8 years (general population: 10.2 years) and lifetime risks of bleeding of 7%, thromboembolism of 17%, and reintervention of 9%.ConclusionsThe low risks of SVD and reintervention support the use of bioprostheses in elderly patients in need of AVR. The estimated life expectancy after AVR was comparable with the general population. The results of this study inform patients and clinicians about the expected outcomes after bioprosthetic AVR and thereby support treatment decision-making. Furthermore, our results can be used as a benchmark for long-term outcomes after transcatheter aortic valve implantation in patients who were eligible for surgery and other (future) alternative treatments (eg, tissue-engineered heart valves). 相似文献
74.
Sea Hing Ong MBBS MRCP Ralf Mueller MD Ulrich Gerckens MD 《Catheterization and cardiovascular interventions》2011,77(7):1071-1075
Transcatheter aortic‐valve implantation is rapidly emerging as an effective, safe, and sustainable alternative for a specific subset of high‐surgical risk and/or inoperable patients with severe aortic stenosis. However, technical challenges remain for this relatively new procedure, not the least mal‐positioning of the transcatheter prosthesis resulting in acute aortic regurgitation. We report a case of deep implantation of a CoreValve prosthesis that was inadvertently pulled out of the aortic annulus during repositioning. The patient received a second sequential CoreValve successfully.© 2010 Wiley‐Liss, Inc. 相似文献
75.
Alfredo Giuseppe Cerillo MD Francesca Chiaramonti MD Michele Murzi MD Stefano Bevilacqua MD Elisa Cerone MD Cataldo Palmieri MD Paolo Del Sarto MD Massimiliano Mariani MD Sergio Berti MD Mattia Glauber MD 《Catheterization and cardiovascular interventions》2011,78(7):987-995
Objective: We report our experience with the transapical transcatheter “Valve in valve” implantation (T‐VIV) in patients with a failed mitral or tricuspid bioprosthesis; we briefly review the pertinent literature, and discuss some technical aspects of this procedure. Background: Redo valve surgery for failure of a mitral or tricuspid bioprosthesis might become extremely challenging, both because of the patients' condition, which is frequently poor, and for the technical aspects of the operation itself, that can be very demanding. T‐VIV has been widely employed with good results for the treatment of aortic bioprosthesis failure, and could represent an attractive option in this setting. Methods: Four patients with multiple comorbidities (age: 63‐83 years; logistic Euroscore: 37.2‐81.5) underwent T‐VIV at our institution for failure of a mitral [ 3 ] or tricuspid [ 1 ] bioprosthesis. A 26mm Sapien valve was used in all cases. All the mitral procedures were performed via a transapical approach. The tricuspid procedure was performed via a transjugular approach. Results: The first mitral procedure was complicated by the splaying of the xenograft stents and embolization of the valve. The procedure was converted to conventional surgery, and the patient died on postoperative day 1. In the subsequent procedures, the valve was positioned more atrially, and was fixed to the malfunctioning xenograft sewing ring. All subsequent procedures were successful, all patients were discharged home and were alive and well at follow‐up. Conclusions: The results of T‐VIV procedure in the mitral position have been suboptimal, and four of the sixteen patients reported to date died. However, all patients were extremely diseased, and some of the reported failures were related to amendable technical factors relative to the surgical access or to the valve deployment technique. With increasing experience, this procedure might become indicated as an alternative to conventional surgery in selected patients, encouraging increased use of bioprosthesis, and marking a pivotal change in the management of valvular disease. © 2011 Wiley Periodicals, Inc. 相似文献
76.
77.
Direct percutaneous transaxillary implantation of a novel self‐expandable transcatheter heart valve for aortic stenosis
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
78.
《Annales de cardiologie et d'angeiologie》2016,65(5):346-351
Transcatheter aortic valve implantation (TAVI) is nowadays a worldwide technique in the field of treating aortic stenosis. One of the main side effects linked to the technique are mostly attached to rhythm disturbances, such as atrioventricular (AV) and intraventricular blocks. Consequently, a pacemaker implantation is often required. That implantation rate is estimated between 8 and 30%, depending on the valve chosen. Thanks to main meta analysis on the subject, it has been managed to isolate the following risks factors for AV block development: preoperative right bundle branch block (RBBB: the most powerful element), complete AV block during the procedure, male gender, a so-called porcelain aorta, the absence of previous valvular surgery, the aortic annulus size (i.e when that size is inferior to the valve's one) and the QRS duration after the procedure (the superior threshold has been set at 128 ms for the Corevalve). The currently recommendations advice to implant a pacemaker are as followed: high grade AV block (in the main studies, the implantation occurs within the 5 days after the TAVI), complete and transient AV block during the TAVI, second degree AV block and RBBB associated with first degree AV block. Our article aims to review the arrhythmic issues of TAVI. 相似文献
79.
《Indian heart journal》2016,68(5):732-736
Transcatheter aortic valve implantation (TAVI) has revolutionized the management of elderly patients with symptomatic severe aortic stenosis in the western world. It is a valuable alternative to surgical aortic valve replacement in patients, who are inoperable or at high surgical risk due to co-morbidities. The prevalence of aortic stenosis increases sharply with age after the sixth decade and is expected to have a significant impact on the geriatric health care system of India, given the rapid increase in life expectancy in recent years. Although a decade has passed since the first TAVI implantation, it is yet to penetrate most of the developing countries in a major way. This short review focuses on fundamentals of initiating a TAVI program based on the experience of a high volume TAVI center with a successful program in Germany. 相似文献
80.
Does my high blood pressure improve your survival? Overall and subgroup learning curves in health
下载免费PDF全文
![点击此处可从《Health economics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Learning curves in health are of interest for a wide range of medical disciplines, healthcare providers, and policy makers. In this paper, we distinguish between three types of learning when identifying overall learning curves: economies of scale, learning from cumulative experience, and human capital depreciation. In addition, we approach the question of how treating more patients with specific characteristics predicts provider performance. To soften collinearity problems, we explore the use of least absolute shrinkage and selection operator regression as a variable selection method and Theil–Goldberger mixed estimation to augment the available information. We use data from the Belgian Transcatheter Aorta Valve Implantation (TAVI) registry, containing information on the first 860 TAVI procedures in Belgium. We find that treating an additional TAVI patient is associated with an increase in the probability of 2‐year survival by about 0.16%‐points. For adverse events like renal failure and stroke, we find that an extra day between procedures is associated with an increase in the probability for these events by 0.12%‐points and 0.07%‐points, respectively. Furthermore, we find evidence for positive learning effects from physicians' experience with defibrillation, treating patients with hypertension, and the use of certain types of replacement valves during the TAVI procedure. 相似文献